Full Press Release Details
Lexicon Enters Into Loan Facility With Oxford Finance for Up to $150 Million to Support Planned Commercialization of Sotagliflozin.
LXRX
Lexicon Enters Into Loan Facility With Oxford Finance for Up to $150 Million to Support Planned Commercialization of Sotagliflozin
Key Takeaway: Lexicon Enters Into Loan Facility With Oxford Finance for Up to $150 Million to Support Planned Commercialization of Sotagliflozin
Price reaction · baseline $2.12 (2022-03-16 close) · hit after-hours · 1 other LXRX headline(s) in the window, move may be shared
day 0 close · peak
+3.8%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+111%
120-day peak, hindsight
Typical move
11%
average across 13 past catalysts
Cash runway
~61 mo
Minimal dilution risk
Lead asset
Sotagliflozin
Phase 3 · Type 1 Diabetes Mellitus